The United States FDA has approved the use of Enhertu combination therapy for first-line treatment of HER2-positive breast cancer.

The FDA has approved the combination of AstraZeneca and Daiichi Sankyo's fam-trastuzumab deruxtecan with trastuzumab for first-line treatment, as the DESTINY-Breast09 trial showed a median progression-free survival of 40.7 months, superior to the standard THP regimen of 26.9 months; trastuzumab is sold by Roche.